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Abstract
Background: Cardiac autonomic neuropathy (CAN) is a common complication of diabetes associated with poor
prognosis. In addition, the autonomic imbalance is associated with cardiovascular disease (CVD) in diabetes. It is
thought that adipocytokines contribute to the increased risk of vascular complications in patients with type 2
diabetes mellitus (T2DM). However, literature data on the association between CAN with adipocytokines such as
leptin, tumor necrosis factor-alpha (TNF-alpha), adiponectin in subjects with T2DM is limited.
Therefore, in the present study, we examined the relationship between fasting serum leptin, TNF- alpha and
adiponectin and CAN in Korean T2DM patients.
Methods: A total of 142 T2DM patients (94 males, 48 females) were recruited. CAN was assessed by the five tests
according to the Ewing’s protocol and the time and frequency domain of the heart rate variability (HRV) was
evaluated. Serum TNF-alpha and adiponectin levels were measured using enzyme-linked immunosorbent assay and
serum leptin levels were measured using radioimmunoassay.
Results: Although, the mean levels of leptin, TNF-alpha and adiponectin were not significantly different between
the groups with and without CAN, the levels of leptin and adiponectin had a tendency to increase as the score of
CAN increased (p = 0.05, p = 0.036). Serum leptin levels demonstrated a negative correlation with low frequency
(LF) in the upright position (p = 0.037). Regarding TNF-alpha, a significant negative correlation was observed with
SDNN and RMSSD in the upright position (p = 0.023, p = 0.019). Adiponectin levels were not related to any HRV
parameters. Multivariate logistic regression analysis demonstrated that the odds of CAN increased with a longer
duration of diabetes (1.25, [1.07-1.47]) and higher homeostatic model of assessment-insulin resistance (HOMA-IR)
(5.47, [1.8-16.5]). The relative risks for the presence of CAN were 14.1 and 51.6 for the adiponectin 2
nd,3
rd tertiles
when compared with first tertile (p-value for trend = 0.022).
Conclusions: In the present study, the higher serum adiponectin levels and HOMA-IR were associated with an
increased risk for the presence of CAN. Also, the CAN score correlated with the serum adiponectin. Serum
adipocytokines such as leptin and TNF-alpha were significantly correlated with parameters of HRV, representative
markers of CAN. Future prospective studies with larger number of patients are required to establish a direct
relationship between plasma adipocytokine concentrations and the development or severity of CAN.
Keywords: Cardiac autonomic neuropathy, heart rate variability, leptin, TNF- alpha, adiponectin, type 2 diabetes
mellitus
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Although cardiac autonomic neuropathy (CAN) is one
of the most common complications of diabetes, it is
commonly overlooked. CAN represents a significant
c a u s eo fm o r b i d i t ya n dm o r t a l i t yi nd i a b e t i cp a t i e n t s
and is associated with a high risk of cardiac arrhythmias
and sudden death, possibly related to silent myocardial
ischemia [1-3].
Autonomic imbalance, characterized by a hyperactive
sympathetic system and a hypoactive parasympathetic
system, is associated with cardiovascular disease (CVD)
in diabetes [4,5]. The heart rate variability (HRV) has
been used to assess autonomic imbalances, diseases and
mortality. Low HRV and sympathetic overactivity are
predictors of CVD.
Although hyperglycemia plays a key role in the devel-
opment of CAN, strict glycemic control cannot abolish
the risk of CAN, suggesting the involvement of other
contributing factors to its development and the need for
their identification [6].
Adipose tissue secretes adipocytokines which have an
impact on glucose and lipid metabolism, the inflamma-
tory process and other bioactivities [7,8]. It is thought
that adipocytokines contribute to the increased risk of
vascular complications in patients with type 2 diabetes
mellitus (T2DM) by modulating vascular function and
affecting inflammatory processes [7,9]. In addition, the
role of the adipocytokines on HRV in various conditions
has attracted considerable attention.
Leptin may play a role as a potential marker for the
diagnosis of obesity-related disease and has been shown to
stimulate the sympathetic nervous system (SNS) [10,11].
In addition, leptin exerts an atherogenic and angiogenetic
effect and is associated with the development of T2DM
and CVD [12]. However, studies examining the impact of
leptin on CAN or HRV in T2DM are limited.
There is now convincing data demonstrating that dia-
betes includes an inflammatory component thought to
be related to diabetic complications. Several reports sup-
port the hypothesis that dysregulation of the TNF
superfamily may be involved in the development of dia-
betic vascular complications [13]. However, literature
data regarding the association between CAN and TNF-
alpha (TNF-a) in subjects with T2DM is limited.
Adiponectin, the most abundant adipocytokine, was
found to be decreased in conditions such as obesity,
insulin resistance, T2DM, its macrovascular complica-
tions and coronary artery disease (CAD) [14]. Siitonen
et al. reported that single nucleotide polymorphisms in
adiponectin receptors may modify the risk of CVD in
individuals with impaired glucose tolerance [15]. In
addition, hypoadiponectinemia is assciated with SNS
overactivity [16]. However, there is still limited
information on regarding the relationship between
plasma adiponectin, T2DM and cardiac autonomic ner-
vous function.
To our knowledge, none of the previously published
studies investigated the effects of leptin, TNF-a,a n d
adiponectin on the presence of CAN in T2DM. There-
fore, in the present study, we examined the relationship
between fasting serum leptin, TNF-a, adiponectin and
CAN in 142 Korean T2DM patients.
Methods
Patients
We recruited 170 diabetic patients who underwent car-
diac autonomic function tests at diabetes clinic of Soon-
chunhyang University Bucheon Hospital, from January
2009 to May 2011. Among the total 170 patients, those
with type 1 diabetes, and were not available of fasting
serum samples were excluded. Also, six patients taking
beta-blockers were excluded. Finally, this study was per-
formed on 142 T2DM patients (94 males and 48
females, mean age: 52.4 years). We reviewed detailed
demographic data, biochemical data, clinical and treat-
ment history using medical records. All patients were
informed of the purpose of the study and their consent
was obtained. The study was approved by the Institu-
tional Review Board of Soonchunhyang University
School of Medicine, Bucheon Hospital.
Cardiac autonomic function test
Autonomic function tests (AFT) were performed in the
morning at a quiet room by the same operator and were
analyzed by one investigator. Subjects were advised to
refrain from smoking, eating, and coffee consumption
for at least 2 hour before the tests.
CAN was assessed by the five standard cardiovascular
reflex tests according to the Ewing’s protocol [17].
Three of these measurements mainly assess parasympa-
thetic function; heart rate responses to deep breathing
(beat-to-beat variation), to standing (30:15 ratio), and to
the Valsalva maneuver. The other two tests mainly
assess sympathetic function; blood pressure responses to
standing and a sustained handgrip. The heart rate
response to deep breathing, standing, and the Valsalva
maneuver were assessed automatically from ECG
recordings using the DICAN evaluation system (Medi-
core Co. Ltd, Korea). The results of each of the above
five tests for the detection of CAN were classified into
three categories based on the severity of abnormality
detected, and each of them was given a definite point as
described by Bellavere et al. [18].
Determination of the CAN score
The severity of CAN was quantitated by summation of
points obtained from each of the five tests, where each
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borderline, or abnormal values, respectively. Conse-
quently, the minimum and maximum autonomic neuro-
pathy points were 0 and 5, respectively. CAN was
defined as the presence of at least two abnormal tests or
an autonomic neuropathy points of ≥ 2 [19].
The CAN score was categorized as follows: CAN score
0 (total points 0), CAN score 1 (points 0.5-1.5), CAN
score 2 (points 2-3), and CAN score 3 (points ≥ 3.5).
CAN was considered absent, early, definite, or severe if
the CAN scores were 0, 1, 2, or 3, respectively.
Time domain and frequency domain of heart rate
variability
Time domain variables The standard deviation of nor-
mal-to-normal RR intervals (SDNN; ms, correlated to
total autonomic activity) and the square root of the
mean of the squares of differences between successive
RR intervals (RMSSD; ms, correlated to parasympathetic
activity) were calculated.
Frequency domain variables Total power in the fre-
quency range (0-0.40 Hz) was divided into: very low fre-
quency (VLF: < 0.04 Hz), low frequency (LF: 0.04-0.15
Hz, modulated by SNS), and high frequency (HF: 0.15-
0.4 Hz, modulated by parasympathetic nervous system
(PNS)). LF and HF measured in normalized units, which
represent the relative value of each power component in
proportion to the total power minus the VLF compo-
nent. The LF/HF ratio, regarded as an index of cardiac
sympathetic/parasympathetic tone balance, was also
calculated.
Measurement of serum adipocytokines
Blood samples were taken after overnight fasting; serum
was separated, stored at -80°C, and were analyzed at a
later time. Serum leptin levels were measured using
radioimmunoassay (Millipore, Billerica, USA). Serum
adiponectin and TNF-a levels were measured using a
commercially available enzyme-linked immunosorbent
assay (ELISA, R&D Systems Inc., Minneapolis, USA).
An automated device (VP-1000; Colin, Japan) was
used to measure arterial pulse wave velocity (PWV) and
ankle-brachial index (ABI). The insulin resistance status
was evaluated by the HOMA-IR index. The HOMA-IR
was calculated by the formula: [fasting insulin (uIU/mL)
x fasting blood glucose (mmol/L)]/22.5. The HOMA-IR
score was available only in 128 patients not receiving
exogeneous insulin.
Statistical analysis
Statistical analysis was performed using SPSS 14.0 (SPSS
Inc, Chicago, IL, U.S.A). Data are reported as mean
standard deviation (SD) for variables which are normally
distributed or as median (minimum-maximum) for vari-
ables which are not normally distributed or as number
of participants (percentages). Non-normally distributed
variables, that is, TG, hsCRP and HOMA-IR were trans-
formed as natural logarithm before analysis. The catego-
rical variables of the groups were compared by Chi-
square test. The significance of the mean differences
between patients with CAN and those without CAN
was evaluated with Student’s t-test. One-way ANOVA
was used to evaluate differences of means among multi-
ple groups. Correlation between plasma adipocytokines
and other clinical parameters were analyzed by Pearson’s
or Spearman’s correlation analysis. We used the odds
ratio (OR) as a measure of the association between adi-
pocytokines or other variables and presence of CAN in
multivariate logistic regression analysis.
Results
The clinical characteristics of the participants
The general characteristics of the study participants are
presented in Table 1. The age of the participants was
52.4 ± 10.0 years, and the mean duration of diabetes
Table 1 General characteristics of the participants
age 52.4 ± 10.0
Men/Women (%) 94/48 (66.2/33.8)
duration of DM(year) 6.1 ± 5.0
Body mass index (kg/m
2) 24.6 ± 3.7
Systolic BP (mmHg) 127.8 ± 14.7
Diastolic BP (mmHg) 78.1 ± 8.6
HbA1C (%) 7.9 ± 1.9 (5.5-16.2)
FPG (mg/dL) 141 (73-377)
eGFR (mL/min/1.73 m
2) 80.6 ± 16.0
Total cholesterol (mg/dL) 168.6 ± 32.0
LDL-cholesterol (mg/dL) 95.2 ± 27.7
Hypertension, n (%) 46 (32.1)
HDL-cholesterol (mg/dL) 47.7 ± 15.2
Triglycerides (mg/dL) 126 (38-1013)
hsCRP (mg/dL) 0.08 (0.03-11.42)
apolipoprotein B (mg/dL) 78.2 ± 22.3
ABI 1.11 ± 0.12
PWV (cm/sec) 1515 ± 248
HOMA-IR 2.69 (0.09-29.01)
smoking, n (%) 47(33.1)
Alcohol, n (%) 62 (43.7)
treatment modality no medication, n (%) 32 (22.7)
OHA, n (%) 97 (68.8)
OHA + Insulin, n (%) 5 (3.5)
Insulin, n (%) 7 (5.0)
Data are shown as mean ± SD, median (minimum-maximum) or as n (%).
FPG: fasting plasma glucose; eGFR: estimated glomerular filtration rate;
LDL: Low density lipoprotein; HDL: high density lipoprotein;
hsCRP: high-sensitivity C-reactive protein; ABI: ankle-brachial index;
PWV: pulse wave velocity; HOMA-IR: Homeostasis model assessment-insulin
resistance;
OHA: oral hypoglycemic agent
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24.6 ± 3.7 kg/m
2. Forty-five (31.7%) patients were trea-
ted for hypertension; 2 (1.3%) with angiotensin convert-
ing enzyme (ACE) inhibitors, 29 (19.3%) with
angiotensin receptor blockers, 16 (10.7%) with calcium
channel blockers.
Prevalence of CAN
The abnormalities detected in the tests for CAN are
shown in Table 2. Of the 142 patients, 46 (32.4%) were
defined as having CAN. The incidence of CAN was
more prevalent in women as compared to men (men:
27.7%, women: 41.7%). Of the five tests used to deter-
mine the CAN score, abnormal responses were most
frequently found in the heart rate response to the deep
breathing test. The postural blood pressure test yielded
the fewest abnormal responses. Among the 21 patients
with newly diagnosed diabetes at baseline, 3 (14.3%)
patients were found to have CAN.
The comparison of mean adipocytokine levels and clinical
variables including HRV parameters according to the
presence of CAN
The clinical characteristics and laboratory findings
according to the presence of CAN are presented in
Table 3. The mean levels of leptin, TNF-a and adipo-
nectin were not significantly different between the
groups with and without CAN, although the adiponectin
level tended to be higher in the CAN group (3138 vs
4185 ng/ml, p = 0.072). Compared to the patients with-
out CAN, patients with CAN were older and had a
longer duration of diabetes. The patients with CAN
were more likely to have hypertension than those with-
out CAN (p = 0.01). The mean levels of PWV were bor-
derline significantly higher in patients with CAN
compared to patients without CAN (p = 0.05). Notably,
Table 2 Prevalence of CAN in all patients
Men women total
Normal Borderline Abnormal Normal Borderline Abnormal Normal Borderline Abnormal
HR response to 51 19 24 16 11 21 67 30 45
deep breathing (54.3) (20.2) (25.5) (33.3) (22.9) (43.8) (47.2) (21.1) (31.7)
lying-to-standing 65 13 16 31 9 8 96 22 24
HR response (69.1) (13.8) (17) (64.6) (18.8) (16.7) (67.6) (15.5) (16.9)
valsalva 59 16 19 29 11 8 88 27 27
maneurver (62.8) (17) (20.2) (60.4) (22.9) (16.7) (62) (19) (19)
Postural BP 76 18 32 15 1 108 33 1
change (80.9) (19.1) (66.7) (31.3) (2.1) (76.1) (23.2) (0.7)
Sustained 57 24 13 25 10 13 82 34 26
handgrip test (60.6) (25.5) (13.8) (52.1) (20.8) (27.1) (57.7) (23.9) (18.3)
CAN(-/+) 68(72.3)/26(27.7) 28(58.3)/20(41.7) 96(67.6)/46(32.4)
Data are expressed as n (%). HR, heart rate; CAN, cardiac autonomic neuropathy
Table 3 The clinical characteristics and laboratory
findings of patients according to the presence of CAN
CAN- CAN+ P-value
Age 51.0 ± 9.7 55.2 ± 10.2 0.021
Men/Women (%) 68/28(71/29) 26/20(56.5/43.5) 0.048
Duration of DM(year) 5.5 ± 4.7 7.5 ± 5.3 0.025
Leptin (ng/ml) 7.25 ± 7.41 8.14 ± 7.31 0.506
TNF-a (pg/ml) 1.93 ± 1.13 2.95 ± 5.51 0.220
Adiponectin (ng/ml) 3138 ± 3010 4185 ± 3615 0.072
Body mass index (kg/m
2) 24.4 ± 3.6 25.0 ± 3.8 0.435
Systolic BP (mmHg) 126.3 ± 14.2 130.9 ± 15.4 0.080
Diastolic BP (mmHg) 77.6 ± 8.2 79.2 ± 9.3 0.308
HbA1C (%) 8.0 ± 2.1 7.9 ± 1.7 0.756
FPG (mg/dL)* 139 (73-377) 148 (88-340) 0.324
eGFR (mL/min/1.73m2) 81.2 ± 14.6 79.3 ± 19.0 0.531
Total cholesterol (mg/dL) 169.1 ± 31.9 167.4 ± 32.6 0.775
LDL-cholesterol (mg/dL) 96.5 ± 28.0 92.6 ± 27.2 0.438
Hypertension, n (%) 24 (25.3) 21 (46.7) 0.010
HDL-cholesterol (mg/dL) 47.6 ± 16.1 47.8 ± 13.2 0.943
Triglycerides (mg/dL)* 137 (38-1013) 121 (52-356) 0.118
hsCRP* 0.09 (0.03-6.59) 0.08 (0.03-11.42) 0.780
Apolipoprotein B (mg/dL) 79.3 ± 23.6 75.7 ± 19.3 0.462
ABI 1.11 ± 0.14 1.12 ± 0.06 0.473
PWV (cm/sec) 1488 ± 242 1575 ± 252 0.050
HOMA-IR* 2.58 (0.09-15.82) 2.87 (0.55-29.01) 0.016
Smoking (%) 32 (33.3) 15 (32.6) 0.545
Alcohol (%) 38 (39.6) 24 (52.2) 0.088
Treatment modality 0.131
No medication 27 (28.1) 5(11.1)
OHA (n/%) 63 (65.6) 34 (75.6)
OHA + Insulin (n/%) 3 (3.1) 2 (4.4)
Insulin (n/%) 3 (3.1) 4 (8.9)
Data are shown as mean ± SD, or as n (%). BMI: Body mass index; FPG: fasting
plasma glucose; HbA1C: hemoglobin A1C; eGFR: estimated glomerular filtration
rate; LDL: Low density lipoprotein; HDL: high density lipoprotein; OHA: oral
hypoglycemic agent *Natural logarithmic transformations were performed
before analysis
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HOMA-IR (p = 0.016) compared with patients without
CAN. However, there were no significant differences in
HbA1C levels and lipid profiles between the two groups.
Table 4 shows the comparisons of parameters of time
and frequency domain of HRV according to the pre-
sence or absence of CAN. The SDNN in the upright
position was significantly decreased in patients with
CAN compared to patients without CAN (p = 0.003).
The participants were divided into four groups
according to the scores of CAN as previously described.
The levels of leptin and adiponectin demonstrate an
increasing trend as the score of CAN increased (p =
0.05 and p = 0.036, respectively) (Table 5).
Bivariate correlation between leptin, TNF-a, adiponectin
and clinical parameters
Bivariate correlation analyses between leptin, TNF-a,
adiponectin and various clinical parameters are shown
in Table 6. Regarding serum leptin levels, significant
positive correlation was found with body mass index
(BMI), triglyceride (TG), high-sensitivity C-reactive pro-
tein (hsCRP) and HOMA-IR. Serum leptin levels exhib-
ited a borderline significant positive correlation with
CAN score. Moreover, the positive correlation between
serum leptin with BMI, TC and TG remained significant
after adjustment for age and sex (r = 0.41, p < 0.001; r =
0.29, p = 0.027; r = 0.53, p < 0.001, respectively).
Serum TNF-a levels showed a positive correlation
with age, hsCRP and mean PWV. After adjustment for
age and sex, the serum TNF-a level consistently showed
positive correlation with the SBP and mean PWV (r =
0.26, p = 0.05; r = 0.29, p = 0.025).
Serum adiponectin levels showed a significant negative
correlations with BMI, systolic blood pressure (SBP),
diastolic blood pressure (DBP), TG, hsCRP and apolipo-
protein B. In addition, serum adiponectin levels demon-
strated a significant positive correlations with duration
of DM and CAN score. After adjustments for age and
sex, the adiponectin level showed a negative correlation
w i t ht h eB M I ,S B P ,D B P ,T G ,a p o Ba n dh s C R P( r=
-0.38, p = 0.003; r = -0.32, p = 0.013; r = -0.28, p =
0.034; r = -0.26, p = 0.043; r = -0.32, p = 0.014; r =
-0.26, p = 0.047) (Adjusted correlation data not shown).
Table 4 Heart rate variability parameters by time and
frequency domain of patients according to the presence
of CAN
Heart rate variability CAN- CAN+ P-value
Supine
HR 72.8 ± 11.3 76.0 ± 11.4 0.114
SDNN (ms) 28.4 ± 14.2 23.9 ± 14.8 0.081
RMSSD (ms) 18.9 ± 15.7 16.8 ± 17.1 0.459
LF (nu) 63.2 ± 20.5 61.9 ± 22.9 0.742
HF (nu) 36.8 ± 20.5 38.1 ± 22.9 0.742
LF/HF 3.4 ± 4.5 3.5 ± 4.9 0.865
Upright
HR 83.5 ± 29.6 81.4 ± 18.4 0.665
SDNN (ms) 25.2 ± 13.8 18.3 ± 10.3 0.003
RMSSD (ms) 19.6 ± 18.3 14.5 ± 10.6 0.081
LF (nu) 65.0 ± 20.1 59.4 ± 21.4 0.130
HF (nu) 35.9 ± 21.0 39.5 ± 21.8 0.346
LF/HF 3.9 ± 5.7 3.3 ± 4.8 0.466
Data are shown as means ± SD. HR: Heart rate; SDNN: standard deviation of
normal-to-normal RR intervals; RMSSD: square root of the average of the sum
of the squares of the differences between adjacent NN intervals; LF: Low
frequency; HF: High frequency
Table 5 The comparisons of mean levels of
adipocytokines according to the scores of CAN
Score of CAN Leptin (ng/ml) TNF-a(pg/ml) adiponectin(ng/ml)
0 5.44 ± 4.4 1.64 ± 0.32 2718 ± 2759
1 7.38 ± 7.5 2.00 ± 1.26 3229 ± 3096
2 8.08 ± 7.3 3.11 ± 5.82 4003 ± 3307
3 12.55 ± 12.3 1.70 ± 0.49 5434 ± 5293
p for trend 0.05 0.784 0.036
Data are shown as mean ± SD.
Table 6 Correlation of serum adiponectin, leptin, and
TNF-a with clinical variables
Leptin TNF-a adiponectin
rp rp R p
Age 0.119 0.159 0.222 0.008 0.129 0.126
Duration of DM -0.057 0.500 0.078 0.359 0.189 0.024
Body mass index 0.481 < 0.001 0.049 0.562 -0.229 0.006
Systolic BP 0.138 0.103 0.151 0.073 -0.172 0.041
Diastolic BP -0.004 0.965 0.065 0.442 -0.210 0.012
HbA1C -0.139 0.103 0.019 0.827 0.037 0.666
FPG* -0.077 0.367 -0.083 0.331 0.016 0.851
eGFR -0.06 0.491 -0.151 0.080 -0.138 0.111
Total cholesterol 0.075 0.392 0.068 0.435 -0.158 0.070
LDL-cholesterol -0.030 0.726 0.060 0.483 -0.096 0.262
HDL-cholesterol -0.033 0.708 0.108 0.218 0.053 0.548
Triglycerides* 0.254 0.003 -0.710 0.405 -0.244 0.004
HsCRP* 0.264 0.005 0.304 0.001 -0.321 0.001
Apolipoprotein B 0.049 0.638 0.007 0.950 -0.344 0.001
mean ABI 0.008 0.929 0.034 0.699 0.077 0.374
mean PWV 0.031 0.722 0.201 0.020 -0.069 0.943
HOMA-IR* 0.301 0.001 -0.051 0.595 -0.174 0.071
CAN score 0.160 0.057 0.117 0.164 0.177 0.035
Leptin - - -0.087 0.304 -0.048 0.570
TNF-a -0.087 0.304 - - 0.028 0.736
Adiponectin -0.048 0.570 0.028 0.736 - -
FPG: fasting plasma glucose; eGFR: estimated glomerular filtration rate; LDL:
Low density lipoprotein; HDL: high density lipoprotein; hsCRP: high sensitivity
c-reactive protein; ABI: ankle-brachial index; PWV: pulse wave velocity; HOMA-
IR: homeostasis model assessment-insulin resistance
*Natural logarithmic transformations were performed before analysis
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adiponectin with HRV parameters
Correlation of serum leptin, TNF-a,a n da d i p o n e c t i n
levels with HRV parameters are shown in Table 7.
The serum leptin levels exhibited a negative correla-
tion with LF in the upright position (r = -0.2, p =
0.037). Regarding TNF-a, a significant negative corre-
lation was observed with SDNN and RMSSD in the
upright position (r = -0.19, p = 0.023; r = -0.2, p =
0.019). Adiponectin was not related to any HRV
variables.
SDNN in supine showed a negative correlation with
age, duration of DM, SBP, DBP (r = -0.24, p = 0.004; r
= -0.22, p = 0.09; r = -0.20, p = 0.017; r = -0.26, p =
0.002, respectively) and a positive correlation with HDL-
C (r = 0.28, p = 0.001). The LF/HF ratio in supine
showed a positive correlation with BMI, DBP and
HOMA-IR (r = 0.30, p = 0.019; r = 0.26, p = 0.047; r =
0.27, p = 0.005) (Data not shown).
Multiple logistic regression analysis for the relationship of
adipocytokines with presence of CAN
To examine the relationship of serum adipocytokines
with the presence of CAN, a multivariate logistic regres-
sion analysis was performed (Table 8).
In multivariate analysis, only the duration of diabetes,
HOMA-IR, and adiponectin were significantly associated
with the presence of CAN. An increased duration of
diabetes and higher HOMA-IR independently increased
the odds for the presence of CAN (OR = 1.25, [1.07-
1.47]; OR = 5.47, [1.80-16.57], respectively). The relative
risks for the presence of CAN were 14.1 and 51.6 for
the adiponectin 2
nd,3
rd tertiles when compared with
first tertile (p-value for trend = 0.022).
Discussion
In the present study, the higher serum adiponectin
levels were associated with an increased probability for
the presence of CAN. In addition, the measured score
of CAN correlated with the serum adiponectin levels.
Among the adipocytokines, adiponectin is widely
known as a beneficial hormone to diabetes and CVD
due to its anti-inflammatory, anti-atherogenic and anti-
diabetic properties [20]. Park et al. reported that central
adiponectin increased pancreatic beta-cell mass and
attenuated insulin resistance in diabetic rats [21]. In our
study, the multiple links of adiponectin to several meta-
bolic risk factors like BMI, BP, TG, apoB, and hsCRP
are all coherently in line with the hypothesis that adipo-
nectin is a protective factor [22]. However, increased
adiponectin levels were associated with a higher prob-
ability of CAN which is independent of the traditional
and nontraditional risk factors in mutivariate logistic
regression analysis in this study. Also, with an increasing
score of CAN, the levels of adiponectin showed a ten-
dency to increase. It is not clear why serum adiponectin
level is positively correlated with the presence and
severity of CAN. One of the possible explanations is
that in response to endothelial dysfunction, oxidative
stress, insulin resistance promoting autonomic dysfunc-
tion, the serum adiponectin may be compensatorily
increased. Conversely, another possible explanation is
that adiponectin may worsen diabetic CAN, although
this appears to be contrary to the concept of adiponec-
tin as a beneficial hormone.
In the present study, we included the evaluation of the
relationship of HRV parameters with the serum adipocy-
tokine levels. SDNN is the most representative para-
meter of HRV. Therefore, low SDNN represents a low
HRV, which primarily indicates a reduction in dynamic
Table 7 Correlation between parameters of HRV and
serum adipocytokine levels
leptin TNF-a adiponectin
rprprp
SDNNsupine 0.10 0.244 -0.03 0.692 -0.05 0.541
SDNNupright 0.09 0.311 -0.19 0.023 -0.06 0.493
RMSSDsupine 0.03 0.771 -0.12 0.159 -0.03 0.715
RMSSDupright 0.14 0.109 -0.20 0.019 -0.04 0.599
LFsupine 0.03 0.680 0.14 0.107 -0.09 0.275
LFupright -0.18 0.037 0.08 0.327 -0.07 0.425
HFsupine -0.04 0.683 -0.14 0.107 0.09 0.277
HFupright 0.15 0.072 -0.07 0.418 0.04 0.605
LFHFsupine 0.02 0.815 0.13 0.133 -0.12 0.171
LFHFupright -0.15 0.086 0.10 0.257 -0.09 0.286
SDNN: Standard deviation of normal-to-normal RR intervals; RMSSD: square
root of the average of the sum of the squares of the differences between
adjacent NN intervals; LF: Low frequency; HF: High frequency Spearman’s
correlation analysis was used for the statistical analyses
Table 8 Multivariate logistic regression analysis with
presence or absence of CAN as the dependent variable
Independent variable Odds ratio (95% CI) P-value (p for trend*)
Age 1.04 (0.95-1.14) 0.453
duration of diabetes 1.25 (1.07-1.47) 0.006
adiponectin 0.005 (0.022*)
1st tertile 1
2nd tertile 14.1 (1.9-105.6) 0.01
3 rd tertile 51.6 (4.8-450) 0.001
HTN 2.19 (0.51-9.34) 0.291
retinopathy 0.75 (0.08-6.86) 0.796
mean PWV 1.003 (0.99-1.01) 0.051
HOMA-IR 5.47 (1.80-16.57) 0.003
Smoking 1.23 (0.311-4.89) 0.765
Alcohol 2.02 (0.55-7.45) 0.289
HTN: Hypertension; PWV: pulse wave velocity;
HOMA-IR: homeostasis model of assessment-insulin resistance
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[23]. In this study, the SDNN in supine showed a nega-
tive correlation with age, BP and a positive correlation
with HDL-C. RMSSD is specific for the parasympathetic
modulation. Decrease in RMSSD accompanying lowered
SDNN is related to high risk of cardiac disease develop-
ment [24].
Our data demonstrated a negative correlation between
the TNF-a and SDNN and RMSSD. These results sug-
gest that the TNF-a promoting inflammatory reaction
may be associated with low HRV and PNS dysfunction
in T2DM patients.
Spectral analysis of HRV (frequency domain mea-
sures) is another tool to evaluate CAN. The LF band
reflects SNS and the HF band reflects PNS activity
[25]. Reduced PNS activity has been found in a num-
ber of cardiac pathologies including diabetic cardio-
myopathies. The reduced PNS activity is also believed
to account for much of the reduced HRV. The LF/HF
ratio indicates overall balance of the ANS. The higher
LF/HF ratio reflects the domination of SNS while a
lower one reflects domination of the PNS. In our data,
the LF/HF ratio in supine showed positive correlation
with insulin resistance assessed by HOMA-IR. This
result is in line with studies showed a pathogenic link
between autonomic dysfunction and insulin resistance
[26,27].
Serum leptin levels showed a negative correlation with
the LF. This indicated that leptin showed negative corre-
lation with parameters of SNS activity and autonomic
balance. These results are inconsistent with those of
previous studies, which generally suggest that leptin is
associated with sympathetic activation [11]. However,
the evidence relating leptin to SNS in type 2 diabetes is
less clear. The majority of cross-sectional clinical studies
reporting a positive correlations between circulating lep-
tin levels and SNS activation indexed by HRV have been
performed in both lean and obese non-diabetic indivi-
duals and not in T2DM patients. Studies regarding the
relationship between leptin and HRV in type 2 diabetes
are rare and have been inconclusive.
In agreement with a previous report by Piestrzenie-
wicz et al., in our present study, adiponectin was not
related to any HRV parameters [28]. Information col-
lected from other studies conducted in groups of
patients with T2DM, suggests that there are possible
links between hypoadiponectinemia and SNS [29,30].
Wakabayashi et al. showed an independent negative
association between the serum adiponectin concentra-
tion and 24 hour LF/HF ratio [16]. Boer-Martins et al.
reported HRV correlated positively with serum adipo-
nectin [31]. However, there is still limited information
on the relationship between plasma adiponectin, T2DM
and cardiac autonomic nervous function.
Although cardiac autonomic function testing utilizing
t h eh e a r tr a t ev a r i a b i l i t yb yE w i n g ’s method is sensitive,
noninvasive and reproducible, these time domain and
frequency domain methods are less affected by the
examiner’s skill and cooperation of the patients. The
strengths of our study are that we examined both
Ewing’s method and time and frequency domain para-
meters for the evaluation of HRV.
The prevalence of CAN in this cohort of Korean type
2 diabetic patients was 32.4%. Of these, 53.5% were
diagnosed as having early CAN. This result is consistent
with other studies [32,33]. In the study of Vinik et al.,
the prevalence of CAN was approximately 34% among
individuals with type 2 diabetes, when diagnostic criteria
are based upon at least two abnormalities in the auto-
nomic function tests [27]. This is comparable with
another Korean data by Moon et al., who reported that
the prevalence of CAN in diabetics is 26.3% and 65.3%
had early CAN [33]. Among the 21 patients with newly
diagnosed diabetes at baseline, three (14.3%) showed
CAN in our study.
In this study, we observed that the prevalence of CAN
was higher in women than in men. In general, sex dif-
ferences have been found in the onset of CAN, with
men presenting with autonomic impairment earlier and
more severity than women [34]. However, in our study,
women participants were older than men (54.5 vs 51.3
years, p = 0.043). We think that this age factor may con-
tribute to the prevalence of CAN. We did observe that
patients with CAN were significantly older than patients
without CAN, and that they also had significantly longer
duration of DM, a higher prevalence of HTN, a higher
levels of HOMA-IR and mean PWV. These observations
are consistent with those of previous studies [35,36].
Especially, higher HOMA-IR levels were associated with
the increased probability of CAN in multivariate logistic
regression analysis. These findings emphasize the role of
insulin resistance, not only in the etiology of the meta-
bolic syndrome, but also as a determinant of cardiovas-
cular autonomic regulation.
In accordance with the results of study by Moon et al.,
out of the five tests used to determine the CAN score,
abnormal responses were most frequently found for the
heart rate response to the deep breathing test [33]. In
contrast, Ko et al., reported that the abnormal response
to valsalva maneuver was the most frequent [37].
Since the hypoglycemia itself also influence the results
of CAN, we reviewed medical records of all participants
for find hypoglycemic attacks. Five patients experienced
hypoglycemia during the last month previous to CAN
tests. However, hypoglycemic events were infrequently
developed (< 2 episodes). In addition, all patients experi-
encing hypoglycemia were classified as group of absence
of CAN. Therefore, we think that the possibility of
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this study is remote.
Several limitations of our study should be addressed.
First, due to the cross-sectional design, we cannot deter-
mine the causative relationship between adiponectin and
CAN complications. Prospective studies are required to
address this important question. Second, because our
study population included individuals who received the
autonomic function test, some characteristics of the pre-
sent study population may be substantially different
from other populations that did not perform complica-
tion study. Therefore, the generalizability of our study
may be limited. Third, the present study included a
small numbers of subjects. A larger number of patients
should be analyzed for the confirmation of our results.
However, our study is meaningful in that this is the first
study in Korean T2DM patients for the evaluation of
several adipocytokines and CAN. Moreover, to our
knowledge, none of the previously published studies
investigated the relationship of adipocytokines with
HRV parameters in Korean T2DM.
In conclusion, the higher serum adiponectin levels
were associated with an increased risk for the presence
of CAN. Longer duration of diabetes and higher insulin
resistance were independently associated with the pre-
sence of CAN in Korean T2DM patients. Serum adipo-
cytokines such as leptin and TNF-a were significantly
correlated with parameters of HRV, representative mar-
kers of CAN. Future prospective studies with larger
numbers of patients are required to establish a direct
relationship between plasma adipocytokine concentra-
tions and the development or severity of CAN.
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